Jens Hasskarl
Overview
Explore the profile of Jens Hasskarl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Le H, Braun K, Nowakowski G, Sermer D, Radford J, Townsend W, et al.
Leuk Lymphoma
. 2023 Feb;
64(3):573-585.
PMID: 36755418
This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional...
2.
Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, et al.
Cancer Med
. 2022 May;
11(24):4889-4899.
PMID: 35619325
The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8 and CD4 CAR T cells. This analysis assessed safety and...
3.
Cartron G, Fox C, Liu F, Kostic A, Hasskarl J, Li D, et al.
Exp Hematol Oncol
. 2022 Mar;
11(1):17.
PMID: 35337365
Background: There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be...
4.
Salles G, Spin P, Liu F, Garcia J, Kim Y, Hasskarl J
Adv Ther
. 2021 May;
38(6):3266-3280.
PMID: 33970454
Most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have exhausted their treatment options and are deemed palliative. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has recently been introduced...
5.
Hasskarl J
Recent Results Cancer Res
. 2018 Aug;
211:101-123.
PMID: 30069763
Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduction pathway. The mTOR pathway regulates cell growth, proliferation and survival, and...
6.
Hasskarl J
Recent Results Cancer Res
. 2014 Apr;
201:373-92.
PMID: 24756805
Everolimus (RAD001, Afinitor®) is an oral protein kinase inhibitor of the mammalian target of rapamycin (mTOR) serine/threonine kinase signal transduction pathway. The mTOR pathway regulates cell growth, proliferation, and survival...
7.
Hasskarl J
Recent Results Cancer Res
. 2014 Apr;
201:145-64.
PMID: 24756790
Sorafenib (BAY 43-9006, Nexavar®) is an oral multiple tyrosine kinase inhibitor. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the Raf-Ras pathway, vascular endothelial growth...
8.
Harder J, Muller M, Fuchs M, Gumpp V, Schmitt-Graeff A, Fischer R, et al.
World J Gastroenterol
. 2014 Jan;
19(48):9334-42.
PMID: 24409060
Aim: To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer. Methods: ID protein expression was analyzed in 129 samples from patients with...
9.
May A, Frey A, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lubbert M, et al.
Histochem Cell Biol
. 2013 Dec;
141(4):431-40.
PMID: 24292846
The inhibitors of DNA binding (ID) inhibit basic helix-loop-helix transcription factors and thereby guide cellular differentiation and proliferation. To elucidate the involvement of IDs in hematopoiesis and acute leukemias (AL),...
10.
Dietrich H, Hu K, Ruffin M, Song D, Bouillaud E, Wang Y, et al.
Eur J Endocrinol
. 2012 Mar;
166(5):821-8.
PMID: 22383336
Objective: This study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PKs) of different doses of a long-acting release (LAR) formulation of pasireotide in healthy subjects. Design: Single-center, open-label,...